UCB and Novartis announced today that they entered into a licensing agreement for cardiovascular and diabetes products in Germany. Under the agreement, UCB has extended commercial rights for the German market to the cardiovascular medication Provas® (valsartan) beyond 2011 and has licensed in commercial rights for two line extensions: Dafiro® (valsartan and amlodipine) and Dafiro HCT® (valsartan, amlodipine and HCT).
The details can be read here.
No comments:
Post a Comment